American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

01 June 2018 - 05 June 2018

High-dose esomeprazole plus aspirin can help prevent oesophageal carcinoma

Dr. Joseph Delano Fule Robles, 20180621015034

High-dose esomeprazole in combination with aspirin can moderately reduce the risk of developing high-grade dysplasia or oesophageal cancer or delay death from any cause in patients with Barrett’s oesophagus (BE).

Taselisib plus fulvestrant shows encouraging results for advanced breast cancer

Dr. Joseph Delano Fule Robles, 20180621014138

The selective PI3K inhibitor taselisib in combination with fulvestrant has demonstrated efficacy in patients with oestrogen receptor (ER)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.

$Once-weekly carfilzomib promising in relapsed/refractory multiple myeloma$

Once-weekly carfilzomib promising in relapsed/refractory multiple myeloma

Christina Lau, 20180620105634

Once-week carfilzomib may represent a more convenient treatment option for patients with relapsed/refractory multiple myeloma (R/R MM), according to data from the phase III ARROW trial.

ARCHER 1050: Dacomitinib shows superior OS vs gefitinib in first-line EGFR-positive NSCLC

Jackey Suen, 20180620100835

The EGFR tyrosine kinase inhibitor (TKI) dacomitinib showed superior overall survival (OS) vs gefitinib in patients with treatment-naïve EGFR-positive non-small-cell lung cancer (NSCLC) in the final analysis of the ARCHER 1050 study.

Adjuvant mFOLFIRINOX extends OS by almost 20 months in pancreatic cancer

Christina Lau, 20180619070739

Adjuvant treatment with a modified FOLFIRINOX (mFOLFIRINOX) regimen extends overall survival (OS) by nearly 20 months compared with standard chemotherapy in patients with nonmetastatic pancreatic ductal adenocarcinoma (PDAC), results of a phase III trial have shown.

TAILORx: Gene expression assay helps spare adjuvant chemo in many breast cancer patients

Christina Lau, 20180612094424

Clinical use of a 21-gene expression assay can help spare adjuvant chemotherapy in many patients with early breast cancer, according to results of a large trial hailed by experts as practice-changing.

KEYNOTE: Most patients with advanced NSCLC can start treatment without chemo

Christina Lau, 20180612072234

Most patients with advanced non-small-cell lung cancer (NSCLC) can have improved overall survival (OS) with first-line pembrolizumab without chemotherapy even if their PD-L1 expression levels are low, results of the phase III KEYNOTE-042 trial have shown.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!

FLAG-GO vs FLAG-Ida regimen leads to better relapse-free survival in CBF acute myeloid leukaemia

Stephen Padilla, 16 Dec 2019

Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.

Switching to ixazomib-based induction feasible, effective in newly diagnosed multiple myeloma

Stephen Padilla, 12 Dec 2019

Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Daratumumab add-on to RVd boosts response rates in transplant-eligible NDMM

Elaine Soliven, 17 Dec 2019

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.